AX-2025-021259

Cagrilintide · 10 mg declared · Bachem Holding (Suzhou) Co., Ltd. · lot BCH-2509-A6666

MARGINALPURITY ONLY

Report ID: AX-2025-021259
Compound: Cagrilintide
Compound class: Incretin analogues and co-agonists
Supplier: BCH — Bachem Holding (Suzhou) Co., Ltd.
Batch / lot: BCH-2509-A6666
Declared label claim: 10mg
Laboratory: Medutest
Assay date: 18 Oct 2025
Submitted: 20 Oct 2025
Quarter: 2025-Q4
Submitter: Contributor #P-1187
Sample provenance: Supplier-supplied

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	99.72	% area	≥ 96.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.28	% area	≤ 3.5	PASS
Largest single impurity	RP-HPLC — des-C16 diacid (−254 Da)	0.14	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	85.43	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	85.19	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	11.23	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	9.567	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	95.7	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	6.16	%	≤ 8.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	8.18	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.23	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.40	EU/mg	≤ 5.0	PASS
Sterility	membrane filtration, USP <71>, 14 d	No growth at 14 d	—	no growth	PASS
Appearance	visual, diffuse light, black and white background	White cake, partial shrinkage from vial wall	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	3.09	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	14.14	min	14.17 ± 0.45 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.12	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	55,800	—	≥ 20,000	PASS
Resolution to nearest impurity	vs disulfide-scrambled isomer	1.63	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 55,800, and skew follows the reported asymmetry factor of 1.12. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.14 % impurity against a 99.72 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Cagrilintide — main peak	14.14	4,846,701	99.72	—
2	des-C16 diacid (−254 Da)	11.12	6,804	0.14	-254.225
3	disulfide-scrambled isomer	14.54	3,888	0.08	0.000
4	cagrilintide dimer (intermolecular disulfide)	17.01	1,944	0.04	+3959.306
5	open-chain (reduced disulfide, +2 Da)	13.13	972	0.02	+2.016
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	6.16
Counter-ion (TFA)	ion chromatography	8.18
Residual solvent + inorganic residue	estimated	0.23
Total peptide content	by difference	85.43
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.5	99.72	divergence +0.19 pp vs batch median
Total impurities (% area)	0.50	0.28
Largest single impurity (% area)	0.28	0.14
Water (%)	5.2	6.16
Counter-ion (%)	3.2	8.18
Peptide content (%w/w)	91.0	85.43
Endotoxin (EU/mg)	not stated	0.40
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 11 d) → assay. Submitter did not handle the vial.
Assay date: 18 Oct 2025
Submitted to the index: 20 Oct 2025
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot BCH-2509-A6666 n=6

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-021254	BCH-2509-A6666	Nordanalyt	2025-Q4	99.42	5.74	93.4	Supplier-supplied	1	MARGINAL
AX-2025-021255	BCH-2509-A6666	PeptideMeter	2025-Q4	99.18	6.77	—	Supplier-supplied	1	MARGINAL
AX-2025-021256	BCH-2509-A6666	Medutest	2025-Q4	99.04	6.47	92.6	Supplier-supplied	1	MARGINAL
AX-2025-021257	BCH-2509-A6666	Janoshik	2025-Q4	99.57	5.99	107.0	Supplier-supplied	1	MARGINAL
AX-2025-021258	BCH-2509-A6666	Nordanalyt	2025-Q4	99.19	5.44	105.3	Supplier-supplied	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Cagrilintide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041747	FGP	FGP-2602-M9870	Nordanalyt	2026-Q2	98.03	3.83	—	Supplier-supplied	0	PASS
AX-2026-041749	FGP	FGP-2602-M9870	Janoshik	2026-Q2	99.47	4.14	—	Supplier-supplied	0	PASS
AX-2026-042749	GGPeps	GGPE-2603-R9581	Medutest	2026-Q2	97.95	6.05	—	Supplier-supplied	1	FAIL
AX-2026-041877	JEEP	JEEP-2603-E3844	Janoshik	2026-Q2	99.61	6.44	—	Supplier-supplied	0	PASS
AX-2026-042386	SWB	SWB-2601-J5083	Janoshik	2026-Q2	99.15	4.21	101.5	Supplier-supplied	0	PASS
AX-2026-041876	JEEP	JEEP-2603-E3844	PeptideMeter	2026-Q2	99.47	6.11	—	Supplier-supplied	1	MARGINAL
AX-2026-041748	FGP	FGP-2602-M9870	PeptideMeter	2026-Q2	98.88	4.01	99.6	Supplier-supplied	0	PASS
AX-2026-041750	FGP	FGP-2602-M9870	Medutest	2026-Q2	98.58	3.43	93.1	Supplier-supplied	0	PASS

Other recent BCH records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043574	N-Acetyl Semax Amide	BCH-2602-E8253	Janoshik	2026-Q3	97.75	8.85	97.9	Supplier-supplied	1	FAIL
AX-2026-043503	BPC-157	BCH-2603-G6422	Janoshik	2026-Q3	98.46	4.32	—	Supplier-supplied	1	MARGINAL
AX-2026-043575	N-Acetyl Semax Amide	BCH-2602-E8253	Janoshik	2026-Q3	97.44	9.19	104.8	Supplier-supplied	1	FAIL
AX-2026-043539	CJC-1295 with DAC	BCH-2607-H7307	Janoshik	2026-Q3	98.12	5.78	100.6	Supplier-supplied	1	MARGINAL
AX-2026-043504	BPC-157	BCH-2603-G6422	Janoshik	2026-Q3	98.38	4.45	95.5	Supplier-supplied	1	MARGINAL
AX-2026-043502	BPC-157	BCH-2603-G6422	PeptideMeter	2026-Q3	97.72	4.86	—	Buyer-sourced	1	FAIL
AX-2026-043501	BPC-157	BCH-2603-G6422	PeptideMeter	2026-Q3	98.37	4.75	100.8	Supplier-supplied	1	MARGINAL
AX-2026-043573	N-Acetyl Semax Amide	BCH-2602-E8253	Janoshik	2026-Q3	97.47	8.59	—	Supplier-supplied	1	FAIL